Latest Spinogenix News & Updates

See the latest news and media coverage for Spinogenix. We track all announcements, press releases, and industry mentions in real time, all in one place.

Spinogenix

Synaptic regenerative therapeutics for brain disorders

spinogenix.com

Headquarters: Los Angeles, United States
Founded year: 2016
Company type: Private company
Number of employees: 4–10

Last updated Today

Latest news about Spinogenix

In short: Spinogenix advanced its synaptic regeneration pipeline, securing FDA Fast Track status for tazbentetol in ALS and launching Phase 2b/3 trials in FXS.

Company announcements

May 5 Spinogenix

Spinogenix receives FDA Fast Track Designation for tazbentetol in ALS

This enables expedited development following Phase 2a results showing slowed decline in patients. The company continues its Expanded Access Program.

May 3 Spinogenix

Spinogenix presents preclinical results on tazbentetol at ARVO 2026

Data show neuroprotective effects in glaucoma and diabetic retinopathy models, preserving retinal cells and visual function. Quote from CEO Stella Sarraf.

May 1 Spinogenix

Spinogenix founder speaks at symposium

Stella Sarraf shares her journey and Spinogenix's progress in synapse regeneration for ALS, Alzheimer’s, schizophrenia, and Fragile X, with positive trial readouts.

April 23 Spinogenix

Spinogenix announces CLARITY Phase 2b/3 trial

It will evaluate oral SPG601 in male Fragile X patients, assessing EEG biomarkers and cognitive outcomes across dose regimens.

Media coverage

May 5 Yahoo Finance

Spinogenix Receives U.S. FDA Fast Track Designation for Tazbentetol for the Treatment of ALS

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve the lives of patients worldwide, today announced...

May 3 Yahoo Finance

Spinogenix to Present Preclinical Results at ARVO 2026 Demonstrating Neuroprotective Effects of Tazbentetol in Glaucoma and Diabetic Retinopathy Models

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, will present this week the results...

April 23 Yahoo Finance

Spinogenix Announces CLARITY: a Phase 2b/3 trial of SPG601 for the Treatment of Fragile X Syndrome

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, is initiating CLARITY, a Phase 2b/3...

April 9 FRAXA Research Foundation

FRAXA Backs Upcoming Phase 2B Trial of SPG601 for Fragile X Syndrome • FRAXA Research Foundation - Finding a Cure for Fragile X Syndrome

Research Updates • Spinogenix, Inc.

Never miss news about Spinogenix

Track Spinogenix and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Spinogenix competitors & trending companies

Browse news for competitors to Spinogenix and other trending companies.